Physician profile
Vipal Soni
NPI 1114018173
$1,577.40
in general payments reported to CMS, 2019-2025
15 companies · $198 in 2025
The $198 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $162 · 2021: $129 · 2022: $294 · 2023: $158 · 2024: $202 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $558.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $363.80 | 2019-2025 | |
| Pfizer INC. | $332.81 | 2019-2025 | |
| Amgen INC. | $277.10 | 2020-2024 | Otezla |
| Abbvie INC. | $159.12 | 2019-2025 | |
| Tersera Therapeutics LLC | $74.06 | 2019 | |
| Sun Pharmaceutical Industries INC. | $67.18 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $56.57 | 2022-2023 | Sotyktu |
| Genzyme Corporation | $55.80 | 2023 | |
| Galderma Laboratories, L.P. | $54.23 | 2019-2025 | |
| Lilly USA, LLC | $52.82 | 2021-2022 | |
| Incyte Corporation | $23.43 | 2022 | |
| Allergan, INC. | $22.11 | 2019 | |
| Almirall LLC | $20.13 | 2022 | |
| Arcutis Biotherapeutics, INC. | $18.24 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vipal Soni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.